Altimmune director receives 48,800 stock options

Altimmune, Inc. director Philip Hodges received a grant of stock options as part of his non-employee director compensation.

Rhea-AI Filing Summary

Altimmune, Inc. director Philip Hodges received a grant of stock options as part of his non-employee director compensation. The award covers 48,800 options to buy common stock at an exercise price of $2.82 per share, expiring on May 1, 2036.

The 48,800 underlying shares become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, as long as Hodges continues to serve the company through each vesting date. This is a compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 48,800 shares

Grant/Award 1 txn

Insider Hodges Philip

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (option to buy)	48,800	$0.00	$0.00

Holdings After Transaction: Stock Options (option to buy) — 48,800 contracts (Direct)

Footnotes (2)

1. F1. The options were granted pursuant to the Company's non-employee director compensation policy.
2. F2. The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.

Key Figures

Options granted: 48,800 options Exercise price: $2.82 per share Expiration date: May 1, 2036 +3 more

6 metrics

Options granted 48,800 options Stock options to buy Altimmune common stock granted to director

Exercise price $2.82 per share Conversion or exercise price of granted options

Expiration date May 1, 2036 Option term for director grant

Underlying shares 48,800 shares Common stock underlying stock option award

Vesting schedule 12 monthly installments Vests over 12 months following May 1, 2026

Post-transaction option holdings (this grant) 48,800 options Total options following transaction for this award

Key Terms

non-employee director compensation policy, stock options, vested and exercisable, underlying security

4 terms

non-employee director compensation policy financial

"The options were granted pursuant to the Company's non-employee director compensation policy."

stock options financial

"Stock Options (option to buy)"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

vested and exercisable financial

"The shares underlying the option become vested and exercisable in substantially equal monthly installments"

underlying security financial

"underlying_security_title": "Common Stock, par value $0.0001""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Altimmune (ALT) director Philip Hodges report?

Philip Hodges reported receiving a grant of stock options for 48,800 shares of Altimmune common stock. The options were awarded as part of the company’s non-employee director compensation policy and represent a compensation grant, not an open-market stock purchase or sale.

How many Altimmune (ALT) shares are covered by Hodges’ new stock options?

The option grant covers 48,800 shares of Altimmune common stock. These shares are issuable upon exercise of the options, which vest in substantially equal monthly installments over 12 months following May 1, 2026, subject to continued service on each vesting date.

What is the exercise price and expiration date of Philip Hodges’ Altimmune options?

The options have an exercise price of $2.82 per share and expire on May 1, 2036. This means Hodges can, once vested, buy Altimmune common stock at $2.82 per share any time before the options expire, subject to plan and agreement terms.

How do Philip Hodges’ Altimmune options vest over time?

The 48,800 options vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026. Vesting is contingent on Hodges’ continued service with Altimmune through each applicable vesting date, aligning compensation with ongoing board service.

Is Hodges’ Form 4 transaction a market buy or sell of Altimmune (ALT) shares?

No, the Form 4 reflects a grant of stock options, not a market trade. The transaction is classified as a grant or award acquisition, providing Hodges with the right to purchase shares in the future, rather than an immediate purchase or sale in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hodges Philip

(Last) (First) (Middle)

910 CLOPPER ROAD

SUITE 201S

(Street)

GAITHERSBURG MARYLAND 20878

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (option to buy)(1)	$2.82	05/01/2026		A		48,800		(2)	05/01/2036	Common Stock, par value $0.0001	48,800	$0	48,800	D

Explanation of Responses:

1. The options were granted pursuant to the Company's non-employee director compensation policy.

2. The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Gregory Weaver, as Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)